Price (delayed)
$6.83
Market cap
$1.43B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.43
Enterprise value
$2.16B
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of ...
Highlights
BCRX's EPS has soared by 64% YoY and by 30% from the previous quarter
The net income has surged by 61% year-on-year and by 28% since the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 17% YoY and by 5% QoQ
BCRX's equity is down by 4.5% year-on-year
Key stats
What are the main financial stats of BCRX
MarketValuationsEarnings
Shares outstanding
208.96M
Market cap
$1.43B
Enterprise value
$2.16B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.13
EV/EBIT
187.14
EV/EBITDA
168.93
EV/Sales
4.8
Revenue
$450.71M
Gross profit
$438.23M
Operating income
-$2.54M
Net income
-$88.88M
EBIT
$11.56M
EBITDA
$12.81M
Free cash flow
-$53.14M
Per shareBalance sheetLiquidity
EPS
-$0.43
EPS diluted
-$0.43
Free cash flow per share
-$0.26
Book value per share
-$2.3
Revenue per share
$2.18
TBVPS
$2.37
Total assets
$490.42M
Total liabilities
$966.35M
Debt
$841.42M
Equity
-$475.93M
Working capital
$261.58M
Debt to equity
-1.77
Current ratio
2.63
Quick ratio
2.49
Net debt/EBITDA
57.5
MarginsEfficiencyDividend
EBITDA margin
2.8%
Gross margin
97.2%
Net margin
-19.7%
Operating margin
-0.6%
Return on assets
-18.5%
Return on equity
N/A
Return on invested capital
1.1%
Return on capital employed
3.5%
Return on sales
2.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCRX stock price
How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-6.82%
1 week
-13.1%
1 month
-17.81%
1 year
48.48%
YTD
-9.18%
QTD
-8.93%
Financial performance
How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$450.71M
Gross profit
$438.23M
Operating income
-$2.54M
Net income
-$88.88M
Gross margin
97.2%
Net margin
-19.7%
BCRX financials
The operating margin has soared by 98% YoY and by 94% from the previous quarter
BCRX's operating income has soared by 98% YoY and by 94% QoQ
BCRX's net margin has soared by 71% YoY and by 34% QoQ
The net income has surged by 61% year-on-year and by 28% since the previous quarter
Growth
What is Biocryst Pharmaceuticals's growth rate over time
BCRX growth chart
Valuation
What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.13
EV/EBIT
187.14
EV/EBITDA
168.93
EV/Sales
4.8
Price to earnings (P/E)
BCRX's EPS has soared by 64% YoY and by 30% from the previous quarter
Price to book (P/B)
BCRX's equity is down by 4.5% year-on-year
Price to sales (P/S)
The P/S is 80% lower than the 5-year quarterly average of 15.9 and 8% lower than the last 4 quarters average of 3.4
BCRX's revenue is up by 36% YoY and by 9% QoQ
Efficiency
How efficient is Biocryst Pharmaceuticals business performance
The ROIC has soared by 148% QoQ and by 110% YoY
BCRX's ROS has soared by 142% from the previous quarter and by 107% YoY
The company's return on assets has surged by 58% YoY and by 27% QoQ
Dividends
What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCRX.
Financial health
How did Biocryst Pharmaceuticals financials performed over time
Assets vs liabilities
Biocryst Pharmaceuticals's total assets is 49% lower than its total liabilities
Biocryst Pharmaceuticals's current ratio has decreased by 21% YoY and by 5% from the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 17% YoY and by 5% QoQ
Debt vs equity
BCRX's debt to equity is up by 4.8% year-on-year
BCRX's equity is down by 4.5% year-on-year
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.